Voyager Therapeutics, Inc. (VYGR) Social Stream

Featured Post From StockTwits About VYGR

$VYGR notable items from the 10-Q:

"In August 2021, we initiated a strategic initiative and reevaluated our existing product candidate portfolio. As a result of this reevaluation, we intend to invest additional resources in our novel capsid screening technology to expand discovery of novel capsids with broad tissue tropism in CNS, cardiac and skeletal tissues. We also plan to advance innovative gene therapy programs that leverage these novel capsids as well as our vectorized antibody technology."

"We are currently evaluating potential options for partnering the future development and commercialization of VY-AADC"

"If we and Neurocrine successfully identify a lead candidate and an AAV capsid for this program and reach agreement on a product profile and product development program, we plan to complete IND enabling studies to evaluate its safety and efficacy"

Shares outstanding increased by a little over 200k. Insignificant.

No more pending lawsuit and expect further cost reductions.